Evidence map›Paper›PMID 39009969›Full record

ArticleBMC infectious diseases2024

Ruthenibacterium lactatiformans isolated from a human blood culture: a first report.

Shougen Sumiyoshi, Shigeto Hamaguchi, Keigo Kimura, Katsuyuki Negishi, Koshi Ninomiya, Manabu Sasaki, Satoshi Kutsuna

Abstract readCase Reports
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shougen SumiyoshiDivision of Infection Control and Prevention, Osaka University, 2-15 Yamadaoka, Suita-Shi, Osaka, 565-0871, Japan. sumisho@hp-infect.med.osaka-u.ac.jp.
Shigeto HamaguchiDivision of Infection Control and Prevention, Osaka University, 2-15 Yamadaoka, Suita-Shi, Osaka, 565-0871, Japan.
Keigo KimuraLaboratory for Clinical Investigation, Osaka University Hospital, Osaka, Japan.
Katsuyuki NegishiDepartment of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Koshi NinomiyaDepartment of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Manabu SasakiDepartment of Neurosurgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Satoshi KutsunaDivision of Infection Control and Prevention, Osaka University, 2-15 Yamadaoka, Suita-Shi, Osaka, 565-0871, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRuthenibacterium lactatiformans, a Gram-stain-negative, rod-shaped, obligate anaerobic bacterium of the Oscillospiraceae family, has not been previously reported in human infections. This study reports the first case of bacteraemia and potential vertebral osteomyelitis caused by Ruthenibacterium lactatiformans. CASE PRESENTATION: An 82-year-old man with a history of diabetes, chronic renal failure, and prior spinal surgery for spondylolisthesis and spinal stenosis presented with fever and lower back pain. Magnetic resonance imaging revealed multiple vertebral osteomyelitis lesions. Initial blood cultures identified methicillin-resistant Staphylococcus aureus (MRSA), which prompted vancomycin treatment. However, repeated blood cultures not only confirmed persistent MRSA, but also detected Gram-negative bacilli (GNB). Despite surgical removal of the spinal hardware and antimicrobial therapy, the patient's osteomyelitis worsened, necessitating transfer for further management. Subsequent analysis using 16S rRNA gene sequencing identified the GNB as Ruthenibacterium lactatiformans.

conclusionsThis is the first documented instance of human infection with Ruthenibacterium lactatiformans, signifying its pathogenic potential in vertebral osteomyelitis. The involvement of anaerobic bacteria and the possibility of polymicrobial infections complicate the diagnosis and treatment of vertebral osteomyelitis. This report underscores the need for caution when identifying the causative organism and selecting an appropriate treatment.

Indexed as

BacteremiaBlood CultureOsteomyelitisAged, 80 and overAnti-Bacterial AgentsGram-Negative Bacterial InfectionsHumansMaleMethicillin-Resistant Staphylococcus aureusRNA, Ribosomal, 16SAnti-Bacterial AgentsRNA, Ribosomal, 16SAnaerobic bacteriaBacteraemiaBlood cultureMRSARuthenibacterium lactatiformansSatellite phenomenonVertebral osteomyelitis

Identifiers

PMID39009969
PMCPMC11247725

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.